2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168009
    NLRP3-IN-45 98%
    NLRP3-IN-45 (D6) is an inhibitor of NLRP3 inflammasome activation, inhibiting the activity of IL-1β (IC50=41.79 nM). NLRP3-IN-45 exerts its effects without affecting the initial stage of NLRP3 inflammasome activation. NLRP3-IN-45 specifically inhibits the activation of NLRP3 inflammasome in the LPS-induced acute lung injury (ALI) mouse model.
    NLRP3-IN-45
  • HY-168023
    NOD1-IN-1 687627-78-7 98%
    NOD1/-IN-1 (Compound 2) is a potent RIPK2 inhibitor with an IC50 value of 0.65 nM determined by ADP-Glo assays. NOD1/-IN-1 selectively inhibits the NOD1 pathway (with an IC50 of 33 nM for NOD1), blocking the production of pro-inflammatory cytokines and thereby reducing inflammation. NOD1/-IN-1 is applicable for research in the field of colitis.
    NOD1-IN-1
  • HY-168024
    NOD1/2-IN-1 98%
    NOD1/2-IN-1 (Compound 18) is a potent RIPK2 inhibitor with an IC50 value of 1.4 nM, as determined by the ADP-Glo assay. NOD1/2-IN-1 blocks the production of pro-inflammatory cytokines by inhibiting the NOD1/NOD2 pathways, with IC50 values of 18 nM and 170 nM for NOD1 and NOD2, respectively, thereby reducing inflammatory responses. NOD1/2-IN-1 can be used in studies related to colitis.
    NOD1/2-IN-1
  • HY-168032
    MAGL-IN-18 3036792-74-9 98%
    MAGL-IN-18 (compound 118) is a potent Monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 0.03 nM.
    MAGL-IN-18
  • HY-168033
    AhR agonist 8 3036895-67-4 98%
    AhR agonist 8 (compound 9) is a potent Aryl Hydrocarbon Receptor (AhR) agonist with an EC50 of 0.154 nM. AhR agonist 8 can be used in the study of psoriasis and atopic dermatitis.
    AhR agonist 8
  • HY-168059
    JAK3-IN-15 98%
    JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces LPS-induced p-JAK3 secretion. JAK3-IN-15 can be used in the study of rheumatoid arthritis.
    JAK3-IN-15
  • HY-168065
    Keap1-Nrf2-IN-22 2955083-85-7 98%
    Keap1-Nrf2-IN-22 (compound 19) is a Keap1-Nrf2 inhibitor， with a KD2 value of 42.2 nM for Keap1. Keap1-Nrf2-IN-22 can be used for the study of acute lung injury (ALI) and cerebral ischemia/reperfusion (I/R) injury.
    Keap1-Nrf2-IN-22
  • HY-168070
    COX-2-IN-48 98%
    COX-2-IN-48 (5-25), a COX-2 inhibitor with an IC50 of 51.7 nM for human COX-2, exerts anti-inflammatory and analgesic effects in various rodent models by inhibiting NF-κB pathway. COX-2-IN-48 (5-25) inhibits the degradation of IκB, the phosphorylation and nuclear translocation of NF-κB p65, and the expression of COX-2 and iNOS.
    COX-2-IN-48
  • HY-168074
    4″-C18 EGCG 98%
    4″-C18 EGCG is a potent inhibitor of α-amylase and α-glucosidase with IC50 values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM.
    4″-C18 EGCG
  • HY-168078
    PD-1/PD-L1-IN-50 98%
    PD-1/PD-L1-IN-50 (Compound LG-12) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-50 increases the secretion of IFN-γ to promote CD8 + T cell activation, and activates the antitumor immunity of T cells.
    PD-1/PD-L1-IN-50
  • HY-168079
    GSK-3β inhibitor 21 98%
    GSK-3β inhibitor 21 (compound 44) is an ATP-competitive GSK-3β inhibitor (IC50=6.06 μM) with anti-amyloid aggregation and tau phosphorylation inhibitory activities. GSK-3β inhibitor 21 can be used in the study of Alzheimer's disease.
    GSK-3β inhibitor 21
  • HY-168080
    PD-1/PD-L1-IN-51 98%
    PD-1/PD-L1-IN-51 (Compound III-4) is a PD-1/PD-L1 inhibitor (IC50: 2.9 nM for hPD-L1). PD-1/PD-L1-IN-51 directly binds to PD-L1 to block the interaction between PD-1/PD-L1 and enhances IFN-γ release. PD-1/PD-L1-IN-51 has tumor inhibitory activity.
    PD-1/PD-L1-IN-51
  • HY-168084
    IL-17-IN-1 98%
    IL-17-IN-1 (26) is an orally active IL-17 inhibitor, with IC50 values of 0.013 μM and 0.004 μM for IL-17A and IL-6 release, respectively. IL-17-IN-1 (26) effectively reduces knee swelling in a rat arthritis model.
    IL-17-IN-1
  • HY-168086
    LSD1-IN-35 2992690-04-5 98%
    LSD1-IN-35 (Compound Z-1) is a selective LSD1 Inhibitor (IC50: 108 nM). LSD1-IN-35 inhibits the demethylation on H3K4me1/2. LSD1-IN-35 is an immunomodulator. LSD1-IN-35 promotes response of gastric cancer cells to T-cell killing effect by decreasing PD-L1 expression and further attenuates the PD-1/PD-L1 interaction.
    LSD1-IN-35
  • HY-168089
    NLRP3-IN-49 98%
    NLRP3-IN-49 (compound Z48) is a potent and specific NLRP3 inhibitor (IC50=0.26 μM in THP-1 cells, IC50=0.21 μM in mouse bone marrow macrophages). NLRP3-IN-49 can directly bind to NLRP3 protein (Kd=1.05 μM), effectively preventing the assembly and activation of NLRP3 inflammasome, thereby exhibiting anti-inflammatory properties. NLRP3-IN-49 can be used in the study of inflammatory bowel disease.
    NLRP3-IN-49
  • HY-168091
    YM-I-26 2585015-90-1 98%
    YM-I-26 is a selective NLRP3 inflammasome inhibitor. YM-I-26 enhances the phagocytosis of β-amyloid protein by mouse microglial BV2 cells and inhibits the production of IL-1β and IL-10. YM-I-26 can be used to study the immunomodulatory activity associated with inflammation.
    YM-I-26
  • HY-168092
    VS-15 951948-78-0 98%
    VS-15, a IDO1 inhibitor, selectively binds the heme-free form of IDO1. VS-15 is described as an iNOS inhibitor based on the reduction of NO production.
    VS-15
  • HY-168129
    GSK3β/mTOR modulator 1 98%
    GSK3β/MTOR MODULATOR 1 (Derivative 2) is the GSK3β/mTOR signaling channel regulator. GSK3β/MTOR MODULATOR 1 can be used for acute lung damage (ALI) and inflammation research.
    GSK3β/mTOR modulator 1
  • HY-168137
    NOD2 agonist 2 98%
    NOD2 agonist 2 (compound 23) enhanced the antigen presentation of mouse bone marrow-derived dendritic cells (BMDCs), highlighting its potential as a vaccine adjuvant.
    NOD2 agonist 2
  • HY-168157
    TLR7 agonist 26 1641544-09-3 98%
    TLR7 agonist 26 (Compound 4) is a potent Toll-like receptor 7 (TLR7) agonist, with an EC50 of 225.5 nM. TLR7 agonist 26 shows immunopotentiating effects.
    TLR7 agonist 26
Cat. No. Product Name / Synonyms Application Reactivity